Clinical Trials Logo

Myocardial Ischemia clinical trials

View clinical trials related to Myocardial Ischemia.

Filter by:

NCT ID: NCT01700322 Completed - Clinical trials for Coronary Artery Disease

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

EST
Start date: August 2012
Phase: Phase 4
Study type: Interventional

Endothelial dysfunction is an important predictor - and a determinant - of adverse clinical outcome. Endothelial function is impaired by coronary artery stenting, a stud from our group has shown that it can be improved by platelet inhibition using clopidogrel. However, clopidogrel unresponsiveness is a known problem, and it has been show that the endothelial effects of clopidogrel tend to wane upon prolonged treatment. Whether a more effective anti-platelet therapy is able to prevent/improve not only thrombotic events but also endothelial dysfunction, with potential positive impact on clinical outcome in patients undergoing coronary artery stenting, is an important hypothesis that needs to be further investigated. To date, evidence regarding "ancillary" (non-platelet-dependent) effects of antiaggregant drugs is very limited. For instance, while their antiplatelet effects, and their beneficial effects in patients with acute coronary syndromes, have been clearly demonstrated in multicentric trials, it remains to be shown whether these drugs also protect endothelial function. Interestingly, some authors suggest that the mortality benefit observed in the PLATO study is at least in part independent of direct antiplatelet effects. No study, to date, has tested the effects of prasugrel and/or ticagrelor on endothelial function. With the present trial, the investigators plan to test the effect of clopidogrel, prasugrel and ticagrelor on endothelial function before and up to 4 weeks after coronary artery stenting. This study will provide important pathophysiologic insight on the relationship between platelet aggregation and endothelial function, two parameters that have been shown to influence patients' prognosis.

NCT ID: NCT01700075 Completed - Clinical trials for Diabetes Mellitus, Type 2

Physical and Chemical Study of Atherosclerosis Mechanisms

PCSAM
Start date: January 2009
Phase: Phase 4
Study type: Interventional

Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.

NCT ID: NCT01699802 Completed - Clinical trials for Ischemic Heart Disease

Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)

Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose is to investigate how the adsorptive capacity of the active carbon filter to carbon dioxide in an anaesthetic gas reflector (AnaConDa) is affected by adding inhaled anaesthetic agent. The hypothesis is that addition of inhaled anaesthetic agent will affect the amount of adsorption of carbon dioxide to the active carbon and thereby affect rebreathing of carbon dioxide.

NCT ID: NCT01699230 Recruiting - Clinical trials for Coronary Atherosclerosis

Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?

CORONOMEGA3
Start date: March 2011
Phase: Phase 3
Study type: Interventional

To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis.

NCT ID: NCT01699048 Completed - Clinical trials for Coronary Artery Disease

The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABG

HREVS
Start date: December 1, 2012
Phase: N/A
Study type: Interventional

Minimally invasive revascularization of the left anterior descending artery followed by stent implantation versus percutaneous coronary intervention or coronary artery bypass in patients with multi-vessel coronary disease

NCT ID: NCT01698372 Completed - Clinical trials for Coronary Artery Disease

Negative Pressure Dressing After Saphenous Vein Harvest

Start date: September 2012
Phase: Phase 1
Study type: Interventional

This study will test the effectiveness of negative pressure wound therapy (using the VAC Prevena device, KCI Canada Inc.) applied to the saphenous vein harvest site after Coronary Artery Bypass Grafting (CABG). When initiated immediately after surgery, this intervention may decrease the incidence of wound infection and non-infectious wound complications. It may decrease wound discomfort and improve mobility and functional recovery of the leg.

NCT ID: NCT01697176 Completed - Clinical trials for Coronary Artery Disease

Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques

OPTION
Start date: August 2010
Phase: N/A
Study type: Observational

This is an observational study of lone Coronary Artery Bypass Grafting procedures with endoscopic vein graft harvesting using best harvesting practices.

NCT ID: NCT01696006 Completed - Clinical trials for Coronary Artery Disease

Perfusion CT Registry

Perfusion CT
Start date: November 22, 2013
Phase:
Study type: Observational

The purpose of this study is to determine whether coronary perfusion computed tomography is effective in the treatment of coronary artery disease.

NCT ID: NCT01690884 Completed - Clinical trials for Coronary Artery Disease

Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The investigators are trying to determine if a single dose of Ticagrelor will increase delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with adenosine reuptake blockade.

NCT ID: NCT01690832 Active, not recruiting - Clinical trials for Coronary Artery Disease

Fenoldopam for Prevention of Acute Kidney Injury

FANCY
Start date: September 2012
Phase: Phase 4
Study type: Interventional

Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury (AKI) when they undergo urgent/emergency coronary angiography. The optimal medical treatment for preventing the occurrence of contrast induced - acute kidney injury is still controversial. Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary studies. Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI already shown to be useful for earlier diagnosis of contrast induced nephropathy. The primary objective of this study is to to test the hypothesis that fenoldopam, in addition to standard treatment, reduce the occurrence of contrast induced - acute kidney injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary angiography and/or percutaneous coronary intervention.